Raglan has a long and successful history of providing corporate finance and investment banking services to a range of Irish and international companies. For the last number of years, Raglan ceased to provide any third-party corporate finance services and is now solely focused upon creating our own companies in-house that can then be rapidly listed on the London stock exchange. Our aim is to complete an IPO within two years post inception of the company. This approach creates value for our shareholders and helps our portfolio companies prepare for the next the next stage of their growth. In 2017, Raglan established a niche pharma services company, Open Orphan, following on from the success of its first rare disease pharma company, Amryt Pharma plc. Open Orphan is a fast-growing niche CRO pharmaceutical services company, which is the world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan plc is comprised of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and is also building out a valuable data platform business. Open Orphan is now listed on the London AIM stock exchange and the Euronext growth exchange. More recently Open Orphan span out their assets, to create Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, with a unique capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. Previously, Raglan established Amryt Pharma Plc which is also listed on the London AIM, Dublin Euronext and the NASDAQ exchanges. Following Amryt’s acquisition of Aegerion Pharmaceuticals in September 2019, it held a market capitalisation in excess of £281m in June 2020 and is now an established European and North America orphan drug company.